Search clinical trials for: Fluticasone Furoate

Total 914 results

GlaxoSmithKline

Completed

Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination

Pulmonary Disease, Chronic Obstructive

Australia
GlaxoSmithKline

Completed

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Asthma

United States, Russian Federation, Peru, Mexico
GlaxoSmithKline

Completed

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

Asthma

Australia
GlaxoSmithKline

Completed

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Germany, Spain, Netherlands, Canada
University of Chicago
GlaxoSmithKline

Completed

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Allergic Rhinitis

United States
University of Chicago
GlaxoSmithKline

Completed

Intranasal Steroids and the Nasal Ocular Response

Seasonal Allergic Rhinitis

United States
GlaxoSmithKline

Completed

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Philippines, Thailand, Korea, Republic of, Norway
GlaxoSmithKline

Completed

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, China, Philippines, Korea, Republic of
GlaxoSmithKline

Completed

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Allergic Rhinitis | Rhinitis, Allergic, Perennial

China
GlaxoSmithKline

Completed

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

Estonia, United States, Canada, Germany, Slovakia, Russian Federation, Hungary
GlaxoSmithKline

Completed

RELOVAIR® Lung Deflation Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
University of Saskatchewan

Completed

Effect of Fluticasone Furoate on Methacholine Challenge

Asthma

Canada
GlaxoSmithKline

Completed

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

Rhinitis, Allergic, Perennial

United States, Argentina, Canada, France, Peru, Italy, Chile
GlaxoSmithKline

Completed

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Asthma

United States
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
Hvidovre University Hospital

Recruiting

Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma

Asthma

Denmark
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
GlaxoSmithKline

Completed

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Asthma

United States, Canada
Johannes Gutenberg University Mainz

Completed

Disulfiram as a Modulator of Amyloid Precursor Protein-processing (DIMAP)

Alcohol Addiction
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

United States
Rush University Medical Center
GlaxoSmithKline

Completed

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Allergic Conjunctivitis to Tree Pollen or Grass Pollen

United States
GlaxoSmithKline

Completed

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Rhinitis, Allergic, Perennial

Thailand
GlaxoSmithKline

Completed

Regulatory AVAMYS Nasal Spray PMS

Rhinitis, Allergic, Perennial and Seasonal

Korea, Republic of
Novartis
Merck Sharp & Dohme LLC

Completed

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

Asthma

France, Germany
University of Chicago
GlaxoSmithKline

Completed

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Allergic Rhinitis

United States
Gilead Sciences

Completed

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Invasive Aspergillosis

France
GlaxoSmithKline

Completed

Relovair PD PK in Chinese Healthy Subjects

Asthma

China
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Bispebjerg Hospital
Rigshospitalet, Denmark

Completed

Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate

Pharmacokinetics

Denmark
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Asthma

Sweden, Australia, New Zealand
Novartis

Completed

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Asthma

Germany, Belgium
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
Federico II University

Unknown

Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children

Allergy
GlaxoSmithKline

Terminated

Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting

Rhinitis, Allergic, Seasonal | Seasonal Allergic Rhinitis
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

COPD

Mexico
GlaxoSmithKline

Completed

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

Asthma

New Zealand
Cornea Research Foundation of America

Terminated

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

Intraocular Pressure | Transplant

United States
GlaxoSmithKline

Completed

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma

Asthma

United Kingdom
Teva Pharmaceuticals USA

Completed

Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation

Seasonal Allergic Rhinitis
Padagis LLC

Completed

Randomized Study to Compare the Bioavailability of Three Mometasone Furoate 0.1% Topical Lotions

Healthy
Organon and Co

Completed

Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)

Asthma
GlaxoSmithKline

Not yet recruiting

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Asthma

United States, Argentina, Japan, Taiwan, Canada, Korea, Republic of, Australia
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma
GlaxoSmithKline

Completed

Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

Asthma

United Kingdom
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
Eurofarma Laboratorios S.A.

Completed

A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)

Mild to Moderate Persistent Allergic Rhinitis

Brazil
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
GlaxoSmithKline

Completed

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Asthma

United States, Argentina, Korea, Republic of, Netherlands, Philippines, Chile

3

Subscribe